2023 World Conference on Lung Cancer (Posters)-EP09.02. Stereotactic Body Radiotherapy Synergizes Immunotherapy in Advanced or Recurrent NSCLC: A Single-center Experience

EP09.02. Stereotactic Body Radiotherapy Synergizes Immunotherapy in Advanced or Recurrent NSCLC: A Single-center Experience - PDF(Slides)

Back to course

Pdf Summary

A study conducted at the Shanghai Chest Hospital aimed to assess the value of combining stereotactic body radiotherapy (SBRT) with immune checkpoint inhibitors (ICI) for the treatment of advanced or recurrent non-small cell lung cancer (NSCLC). The study included 150 patients who received SBRT concurrently with ICI between January 2017 and December 2021. The patients were divided into two groups based on when the SBRT was delivered: either initially or during later-line ICI treatment (Group 1) or after disease progression (Group 2). <br /><br />The results showed that the combination of SBRT and ICI demonstrated favorable survival outcomes for advanced or recurrent NSCLC. The median progression-free survival (PFS) for all patients was 14.3 months, and the median overall survival (OS) was 52.8 months. In Group 1, the median PFS was 20.3 months, while the median OS was not reached. In Group 2, the median PFS was 8.0 months, and the median OS was 30.6 months.<br /><br />The study suggests that SBRT performed in a controlled-disease situation, such as delivering it initially or during first-line ICI treatment, may synergize with immunotherapy and lead to a more promising outcome compared to SBRT delivered after disease progression. The results indicate the potential benefit of combining SBRT with ICI, especially for patients with PD-L1-negative tumors.<br /><br />This study adds to the growing body of evidence supporting the use of SBRT in combination with ICI for the treatment of advanced or recurrent NSCLC. Further research is needed to determine the optimal timing and sequencing of SBRT and ICI and to identify the patient populations that would benefit the most from this combination therapy.

Asset Subtitle

Dan Yao

Meta Tag

Speaker Dan Yao

Topic Metastatic NSCLC: Local Therapies - Integration With Systemic Therapies

Keywords

Shanghai Chest Hospital

stereotactic body radiotherapy

immune checkpoint inhibitors

advanced non-small cell lung cancer

recurrent NSCLC

SBRT and ICI combination

progression-free survival

overall survival

controlled-disease situation

PD-L1-negative tumors